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 ABSTRACT 
Vulvar Squamous Cell Carcinoma (VSCC) can be divided into two subgroups 
basaloid and/or warty (HPV-associated) and keratinizing/non-keratinizing carcinomas (not 
HPV-associated). 
 
The inguinal lymph node status represents the most powerful prognostic factor. The 
Sentinel Node (SN) procedure is an alternative to complete inguinofemoral 
lymphadenectomy, which diminishes the complications. In this thesis the value of 
preoperative lymphoscintigraphy and the SN procedure was assessed. It was 
discovered that the relation between SNs detected on the scintigram and those found 
during surgery showed good agreement using Weighted Kappa. The detection rate of 
SN was 98% for radioisotope plus blue dye, and 94% for blue dye alone. The false 
negative rate was 2.7%. 
Hr-HPV (16, 18, 33, or 52) was detected in 31% of the tumours and in 43% of the 
SNs in patients with HPV-positive tumours. Patients with HPV-positive VSCC were 
significantly younger at diagnosis and had better survival. SNs with metastases were 
more frequently HPV-positive than those without metastases. 
As in many other cancer forms, there is a need for new and better prognostic markers 
in vulvar cancers. High expression of ln-5γ2 chain and HPV negativity were 
associated with poor outcome.  In a multivariate analysis only HPV status and tumour 
stage were significant factors for survival. Ln-5γ2 expression showed positively 
significant correlation with stage, tumour-size, grade and metastases, but was 
negatively associated with HPV status.  Expression of the proliferation marker Ki-67 
was significantly correlated with HPV status. 
Studies of the proteome characteristics of HPV- positive versus HPV-negative VSCC 
by protein and pathway profiling on a global and individual tumour level detected 
four proteins as playing a major role in discriminating relapse from non-relapse 
tumours: STAT1, MX1, LGMN and PSMA5. Validation by immunohistochemistry 
showed significant down-regulation in HPV-positive compared to HPV-negative 
tumours. In the individual tumour pathway analysis, the pathways “RIG-1 like 
receptors in antiviral innate immunity” and “Rac signalling” emerge discriminate for 
separating relapse from non-relapse. 
 
In conclusion; preoperative scintigram gives the best estimate of the accurate number 
of lymph nodes but cannot determine if unilateral or bilateral groins should be 
explored in cases of midline tumours. Presence of HPV DNA in SN was related to 
metastatic disease but did not affect survival. 
High expression of ln-5y2 chain and HPV negativity were associated with poor 
outcome. However in multivariate analysis only HPV status and FIGO-stage showed 
significant relation to survival. Alterations of the “RIG-1 like receptors in antiviral 
innate immunity” pathway may be linked to an unfavourable prognosis, while 
alterations of the “IFN/EGFR/Glucocorticoid” signalling pathway is associated with 
HPV-positive tumours and thus of favourable prognosis.   
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1 INTRODUCTION 
1.1 BACKGROUND AND EPIDEMIOLOGY 
Cancer in the female genital organs constitutes approximately 12% of all female 
cancer. [1].  Vulvar cancer (VC) accounts for about 4% (app. 140 cases/year ) of all 
gynaecological cancers in Sweden and for about 3% of all gynaecological cancers in 
the US [2]. It mostly affects older women. Vulvar squamous Cell Carcinoma (VSCC) 
accounts histologically for 90% of vulvar cancers [3] and is, according to the WHO 
classification subdivided into basaloid, warty, verrucoid and keratinizing/non-
keratinizing carcinomas [4-6]. Melanomas, adenocarcinomas, basal-cell carcinomas 
and sarcomas constitute the remainder. Dissemination of VSCC is predominantly 
lymphogenic to the inguinofemoral nodes. Distant metastases are rare. The overall 
survival rate is < 60%, (Cancer incidence in Sweden 2008). The incidence of VSCC 
varies, with the highest incidence in Europe and North America and the lowest in 
developing countries [2]. The differences may, to some extent, be explained by 
insufficient reporting of cases from the developing countries likely to be influenced 
by low life expectancy. Recent data indicates that invasive vulvar carcinoma, and 
especially its precursor lesions Vulvar Intraepithelial Neoplasia (VIN), have increased 
in incidence. According to a population-based study in Norway, the incidence of VIN 
has increased threefold between the periods 1973 to 1977 and 1988 to 1992 [7]. 
Another study from the US showed that vulvar carcinoma in situ has increased by 
411% from 1973 to 2000 and invasive vulvar cancer by 20% [8]. Studies from the 
National Cancer Institute identified vulvar carcinoma as one of 12 cancers with an 
increase in incidence between 1992 and 1998; the increase has occurred 
predominantly among females younger than 65 [9]. In another study from the US an 
increase of VIN III by 3.5% per year and invasive cancer by 1% per year was 
reported [10]. In a European study patients treated for  VC at the university hospital 
in Dusseldorf doubled in the last three decades and there was an almost fourfold 
increase in younger patients [11]. However, in a population based study from the 
Netherlands, the incidence of usual VIN and differentiated VIN increased between 
1992 and 2005, while the incidence of VSCC remained stable [12]. 
In Sweden the age standardized incidence rate of VSCC shows a significant decrease 
depending on a significant decrease (p=0.002) among elderly women (50 to >85 
years) while the incidence rate for women 0-49 years shows a slight increase 
(p=0.066) (figure 1a-c).  
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figure 1, Age standardized incidence 
rate of Vulvar Squamous Cell carcinoma 
(VSCC)  per 100 000 by calendar year 
1a;All women . 1b; Women 0-49 years. 
1c; Women 50 to > 85 years. Standard 
population: the Swedish female 
population 2000 (data from cancer 
incidence in Sweden 2008) not previously 
published 
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1.2 ETIOLOGIC FACTORS 
The development of VSCC follows two separate pathways of which one is associated with 
HPV and the other is not [4-6]. Classic or usual VIN lesions (figure 2), showing a high rate of 
HPV infection are precursor of the HPV associated type. Histologically the carcinomas are 
non-keratinizing basaloid and/or warty (figure 2) and contain hr-HPV predominantly 16 and 
18. Women with HPV-positive tumours are generally younger, show a high rate of multifocal 
disease and often associated cervical, vaginal and anal intraepithelial neoplasia. Tumours of 
the other pathway are keratinizing/non-keratinizing carcinomas, commonly HPV-negative, 
associated with differentiated VIN (figure 2) and lichen sclerosus (LS) [13-16].  
The proportion of HPV-positive VSCC varies from 9 to 70% in different studies [13, 17-23].  
The proportion of HPV-positive VSCC in Sweden has not been previously investigated and 
although the presence of HPV has been examined in SN in cervical carcinoma and in lymph 
nodes in general in VSCC [20, 23], we have not found any studies on the presence of HPV in 
SN in VSCC. 
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1.2.1 The oncogenic pathway of HPV-positive VSCC 
It is well established that hr-HPV´s are the cause of cervical carcinoma, of which 
99% are HPV- positive [24, 25], and play a role in other malignancies including head 
and neck cancer, penile cancer and vulvar cancer.   
The hr-HPV viruses exert their oncogenic capacity primarily via the viral proteins E6 
and E7, which are the primary transforming viral proteins targeting two major cellular 
regulators, the retinoblastoma protein family (pRB) and p53.  By blocking p53 and 
pRb controlled pathways, E6 and E7 keep infected cells in a proliferative state which 
is necessary for viral DNA synthesis [26]. Gene expression profiles of HPV-positive 
and HPV-negative cancers show differences in cell cycle genes with an up-regulation 
in HPV-positive tumours. Mediated by E2F activity, causing over-expression of E2F 
regulated genes [27].  
E6 and E7 also act to prevent the antiviral and anti-tumour effects of the Interferon 
(IFN)-mediated immune response [28]. Thus by evading the immune system, the 
HPV infection is maintained.  
 
1.2.2 The oncogenic pathway of HPV-negative VSCC 
In contrast to HPV-positive VSCC, little is known about what pathways are 
deregulated in the HPV-negative VC [29-31]. It has been  speculated whether an 
unknown viral aetiology (unidentified types of HPV or novel polyomaviruses) in fact 
causes those HPV-negative vulvar carcinomas [32]. HPV- negative cancer is 
associated with differentiated VIN and/or LS.  Most of the differentiated VINs  are 
associated with p53 mutations or deletions.  Differentiated VINs and VSCC have 
been shown to share identical p53 mutations supporting a pathogenic connection [30]. 
The poorest disease-specific survival in vulvar carcinoma is seen in HPV-negative 
tumours with high p53 protein levels and low p14 (ARF) [21].  It is not known if in 
VSCC the same protein networks that are main drivers in HPV/non-HPV are also 
main drivers in relapse/non-relapse tumours.  
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Figure 2 .Histology of HPV-associated classical Vulvar Intraepithelial Neoplasia (VIN) 
III and Basaloid Vulvar Squamous Cell carcinoma (VSCC) in upper panel, and not HPV-
associated differentiated VIN III and well differentiated keratinizing VSCC in lower panel. 
All specimens are stained with H&E. 
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1.3 STAGING 
The Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) has developed 
a system for staging gynaecological malignancies, including VC. The purpose of the 
classification system is to support clinicians in classifying and staging the tumours in 
order to plan treatment, provide an indication of prognosis, assist in the evaluation of 
the results of treatment and facilitate the exchange of information. 
For VSCC, inguinofemoral nodal status is the most important prognostic factor, 
mainly dependent on the primary tumour size and depth of invasion [3, 33-45]. In 
1988, the FIGO classification was changed from a clinical into a surgico-pathologic 
staging  because of the inability to accurately predict lymph node status by physical 
examination (table 1) [46].  A revised FIGO classif ication system for VSCC was 
introduced in 2009 (table 2) [ 47, 48]  consisting of four major changes [49]. 
 
 
Table 1. The “ old”  FIGO classification of vulvar squamous cell carcinoma from 
1988 
Carcinoma of the vulva 
Stage 1 Lesions ≤ 2cm in size confined to the vulva or perineum, no 
nodal metastasis 
IA Lesions  ≤ 2 cm in size, confined to the vulva or perineum 
with stromal invasion ≤ 1.0mm*,  no nodal metastases  
IB Lesions ≤ 2 cm in size, confined to the vulva or perineum 
with stromal invasion > 1.0mm, no nodal metastases  
Stage II  Tumour >2cm in largest dimension confined to the vulva or 
perineum, no nodal metastases 
Stage III Tumour of any size with adjacent spread to the lower urethra, 
the vagina, or the anus with unilateral regional lymph node 
metastasis 
Stage IVA Tumour invading any of the following: upper urethra, bladder 
mucosa, rectal mucosa, pelvic bone or bilateral regional 
nodes. 
Stage IVB Any distant metastases including pelvic lymph nodes 
*The depth of invasion is defined as the measurement of the tumour from the 
epithelial-stromal junction of the adjacent most superficial papilla to the deepest point 
of invasion. 
 
 
 6 
• Stage II (> 2cm) and IB (≤ 2cm) have been combined because these two 
categories of patients did not appear to differ in survival [ 39] . Tumours 
with negative node status are at low risk regardless the diameter of the 
tumour [ 35] .  
• Stage III represented a heterogeneous group of patients with both 
negative and positive lymph nodes. Because of their good prognosis  
patients with tumours involving the vagina and/ or urethra with negative 
nodes [ 35, 38]  are now classif ied as stage II (formerly stage III). 
• Patients with positive nodes are still classif ied as stage III. The number of 
the involved nodes and morphology (size of the metastasis and presence 
of extra nodal growth is taken into account). An increasing number of 
positive lymph nodes and a larger diameter of nodal metastases both lead 
to a worse survival rate [ 34-36] . Nodal metastases with extra nodal 
spread have a worse prognosis compared to patients with the metastases 
conf ined to the lymph nodes [ 36, 37, 40]  and are now classif ied as 
stage IIIC. 
• The bilaterality of positive nodes has been discounted because it turned 
out not to be an independent prognostic factor when a correction is 
made for the number of positive lymph nodes [ 33] . 
In this thesis we have used the old staging from 1988 since the new staging 
was introduced in 2009 after the inclusion of patients was finished.  
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Table 2. The”  new”  FIGO classification of vulvar squamous cell carcinoma from 
2009 
 
Carcinoma of the vulva 
Stage 1   Tumour confined to the vulva or perineum,  
IA ≤ 2cm in size with stromal invasion ≤ 1mm*, negative nodes 
 
IB ≤ 2cm in size or with stromal invasion > 1mm, negative nodes 
Stage II Tumour of any size with adjacent spread (1/3 lower urethra, 1/3 
lower vagina, anus), negative nodes 
 
Stage III Tumour of any size with or without extension to adjacent perineal 
structures (lower urethra, lower vagina, anus) with  positive 
inguino-femoral lymph nodes 
 
III A Tumour of any size with positive inguino-femoral lymph nodes 
with 1 lymph node metastasis ≥ 5 mm or  1-2 lymph node 
metastasis(es) < 5 mm 
III B With 2 or more lymph nodes metastases ≥ 5 mm or 3 or more 
lymph nodes metastases < 5 mm 
III C With positive node(s) with extra capsular spread 
Stage IV Tumour invades other regional structures (2/3 upper urethra, 2/3 
upper vagina), bladder mucosa, rectal mucosa, or distant 
metastases 
IV A Tumour invades any of the following: upper urethral and/or 
vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to the 
pelvic bone, or fixed or ulcerated inguinofemoral lymph nodes  
IV B Any distant metastasis including pelvic lymph nodes. 
*The depth of invasion is defined as the measurement of the tumour from the epithelial-
stromal junction of the adjacent most superficial papilla to the deepest point of invasion. 
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1.4 SYMPTOMS AND DIAGNOSIS 
Long-term pruritus is the most prominent symptom of vulvar cancer. Other common 
symptoms are lump or mass on the vulva, bleeding, pain, discharge or urinary tract 
symptoms [50, 51]. 
Clinical examination with palpation, inspection and histopathological examination of 
biopsies from all suspicious areas in the vulva such as warty, cauliflower-like lumps, 
ulcers and pigmented areas found the basis.  Fine-needle aspiration of enlarged lymph 
nodes is done to verify metastases. MRI is used to explore involvement of the anal 
sphincter and adjacent tissues [52].  
Today we have no non-invasive methods that can predict the presence of positive 
lymph nodes with accuracy. Not even ultrasound [53, 54], MRI, [52] CT or PET [55]  
can allow us to refrain from inguinofemoral lymph node resection [56-59] with 
exception for microinvasive tumours [60, 61]. The negative predictive value is not 
high enough. 
The lymphadenectomy causes morbidity. The complication rate of complete 
inguinofemoral lymphadenectomy varies between 24 and 70% [62]. Common short-
term complications are infection and wound breakdown while long-term 
complications include lymph oedema, lymphatic cysts and chronic cellulitis of the 
legs [63-66]. The lymphatic drainage of the vulva was described in 1983 [67], with a 
well defined direction of the lymphatic flow to the groins. 
 
 
1.5 THE SENTINEL NODE CONCEPT 
The sentinel node (SN) concept is based on the assumption that all spread from the 
tumour goes through one or several primary draining lymph nodes (SNs) [68-70]. If 
this/these are tumour free, all other nodes should be disease-free. Therefore, a non-
metastatic SN may allow the removal of only this lymph node (figure 3). The SN 
approach is attractive since it could reduce complications caused by the 
lymphadenectomy but still allow staging of the tumour. SN procedure is an 
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alternative to complete inguinofemoral lymph adenectomy that reduces postoperative 
complications [71].  
 
 
Figure 3.  The Sentinel Node (SN) concept. All spread from the tumour will pass the 
SN.  If this node is tumour free all other nodes should be disease free, and can allow 
us to only remove the SN. 
 
In gynaecological surgery there are some experiences of the SN technique from 
cervical cancer, endometrial cancer and vaginal cancer [72-74], but its main use has 
been in vulvar surgery. Studies where the SN detection was followed by complete 
inguinofemoral lymphadenectomy suggest that the SN procedure is highly accurate in 
identifying lymph node metastases with a negative predictive value approaching 
100% [68-70, 75]. The optimal design to prove safety and clinical utility would be an 
equivalent randomized trial (RCT) in which patients with a negative SN are randomly 
assigned to either observation alone or inguinofemoral lymphadenectomy. However, 
an RCT is difficult to perform due to low incidence. Recently, a large multicenter 
observational study provided level 3 evidence indicating that it appears safe to omit 
inguinofemoral lymphadenectomy in case of a negative SN [76].  Hopefully the 
follow-up study “Groningen International Study on Sentinel Nodes in vulvar cancer 
(GROINSS-V-II) trial” will answer the question of whether radiotherapy alone is 
sufficient treatment in cases with a positive SN. 
In breast cancer the SN procedure is now routine [77]. In cutaneous melanoma SN is 
used for staging of the regional lymphatic nodes [78]. After an initial learning period  
the false negative rate in breast cancer is about 3 % [79], while the rate in vulvar 
cancer ranges from 0 to 6% [62, 68-70, 75, 80].  
TUMOUR 
 
SENTINEL 
LYMPH NODE NON-SENTINEL NODES 
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Although the presence of HPV has been examined in SN in cervical carcinoma and in 
lymph nodes in general [20, 23], we have not found any studies on the presence of 
HPV in SN in VSCC. The presence of HPV in SN has been suggested to be a 
diagnostic marker of metastatic involvement in cervical cancer [81, 82].  
 
 
1.6 TREATMENT 
1.6.1 Surgery 
Surgery is the first choice of treatment; both in early and more advanced cases [83]. 
The treatment has gone from large “butterfly resections” of vulva and inguinofemoral 
lymph nodes en bloc to less radical surgery [84, 85]. In early cases wide local 
resection or vulvectomy and inguinofemoral lymphadenectomy through separate 
incisions has been the standard treatment [86, 87]. If the lesion is located ≥ 1 cm 
lateral of the midline, lymphadenectomy will be unilateral, otherwise it will be 
bilateral [41].  In stage IA (invasion depth <1mm) it is considered safe to omit 
inguinofemoral lymphadenectomy because of negligible risk of lymph node 
metastases [60, 61]. It is necessary to obtain at least 8mm pathological margins that 
coincide with approximately 2cm on fresh tissue [41, 85]. The aim is to get local 
control while sparing as much tissue as possible. Surgery is also performed in more 
advanced stages with lymph node metastases [88, 89]. Locally advanced disease 
comprises about one third of all cases at time of diagnosis [90]. Ultra radical surgery 
appears to be a reasonable treatment for locally advanced but resectable tumours, 
especially in the absence of nodal metastases.  The surgical treatment is mutilating 
and causes sexual and psychological problems [91-93]. 
To reduce postoperative complications and mutilation the surgery has, during the past 
years been more individualised including radical local excision and preoperative SN 
technique [76, 94, 95].  
 
1.6.2 Radiotherapy and Chemotherapy 
Radiotherapy is given postoperatively if metastases in the regional lymph nodes 
and/or the tumour margins are not good enough. It can also be given as neoadjuvant 
therapy in combination with chemotherapy to shrink the tumour and make it operable; 
the possibilities of avoiding local organ resection increases and radiotherapy gives 
tumour control comparable to surgery in locally advanced disease [96-98]. 
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Chemotherapy can be given alone as palliative treatment or combined with 
radiotherapy in a curative intention [99].  A combination of treatment modalities 
radiotherapy, surgery and chemotherapy can optimize the treatment [88, 95]. 
 
1.7 PROGNOSTIC FACTORS 
1.7.1 Lymph node metastases 
The presence or absence of lymph node metastasis in the groins represents the most 
powerful prognostic factor for recurrence and survival in VC [3, 33-45].  The new 
FIGO-staging  from 2009 gives a much better estimate of prognosis for patients 
with VC [ 49] . 
Five-year survival is 70-90 % for women without metastases and 25-41% for patients 
with metastatic spread to regional lymph nodes [3, 33, 100]. The numbers of involved 
nodes further discriminate as well as periglandular growth [36, 37, 40]. Studies on 
histopathologic characteristics such as depth of invasion, tumour diameter, and 
localisation of tumour as well as lymph space involvement and grade have been 
performed with the aim to identify patients with low risk of lymph node metastases. 
The results have been contradictory [3] and it seems impossible to define a low risk 
group based on these factors. Only in patients with tumours with ≤ 1mm invasion is it 
accepted to omit inguinofemoral lymphadenectomy [60, 61]. 
 
1.7.2 HPV-status in tumours and SN 
HPV-status seems also to influence the prognosis in VSCC [101]. A better prognosis 
for patients with HPV-positive tumours has been indicated by some studies [21, 23, 
102-104], while other investigators found no prognostic significance associated with 
HPV status [20, 68, 105]. 
The prognostic significance of HPV DNA in lymph nodes in cervical cancer has been 
discussed and HPV presence has been suggested to be a diagnostic marker of 
metastatic involvement [81, 82].  
 
1.7.3 Molecular markers 
In order to improve the treatment and follow-up of vulvar cancer patients, the 
importance of various molecular markers  has been studied [106]. However, so far no 
conclusion regarding the prognostic value of these markers could be drawn due to the 
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small numbers of patients included in each study, and lack of multivariate analysis.  
Moreover most studies have not controlled for HPV-status of the tumours. 
 
1.7.4 Laminin 5 γ2 chain (Ln-5 γ2 - chain) 
 
Tumour invasion is characterized by the tumour cells crossing the basement 
membrane (BM) marking the difference between a malignant and benign tumour 
[107]. Ln5 are molecules of the BM, which separates the epithelium from the 
underlying connective tissue. The laminin family is a group of large cross-shaped 
heterotrimeric proteins composed of three subunits; one heavy α-chains and two light 
β-chains [108]. At least 12 different laminins are identified [109]. They are 
synthesized by numerous cell types and expression of laminin isoforms are cell- and 
tissue specific [109] with different biological functions [108].   
Ln-5 is produced only by the epithelial cells and consists of α3, β3 and γ2 chains. 
These three subunits are coded by specific genes: the LAMA3 gene on chromosome 
18q11.2 (α 3) LAMB3 gene on chromosome lq32 (β 3) and LAMC2 on lq25-31 (γ 2) 
[110, 111]. Accumulating data suggest that ln5 is involved in tumour cell invasion 
and the isoforms (α3, β3 and γ2) plays an important role in epithelial cell adhesion to 
BM and in cell migration [108]. 
 
In normal tissues ln-5 γ2 chain has an important function in the static adhesion of 
epithelial cells to the BM through the attachments to integrins and the assembly of 
hemidesmosomes. 
Studies have shown that the γ2 chain of ln5 is expressed by the migrating but not by 
the stationary keratinocytes in wound healing in skin [110]. In invading cancer cells 
over expressed ln γ2 chain appears to be present in a monomeric form as laminin α3 
and β3 are absent or found in much lower levels. 
Several immunohistochemistry (IHC) studies have reported that ln-5 γ2 chain 
expression is up-regulated in invading cancer cells, suggesting it as a marker of 
invasiveness in SCC and other epithelial carcinomas such as cervical, multifocal 
anogenital, and colon carcinoma [112-116]. Increased expression of ln5 γ2 chain has 
also been correlated with a more aggressive behaviour of the tumour [113, 117-121]  
and ln-5 γ2 chain has also been revealed as a marker for microinvasiveness in cervical 
and vulvar carcinomas [114, 115]. 
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Based on this data the question arose if ln-5 γ2 chain expression could add prognostic 
information in VC. 
 
1.7.5 DNA ploidy and proliferative markers 
DNA ploidy is an established prognostic factor in endometrial and breast carcinomas 
[122, 123], and S Phase Fraction (SPF) and Ki-67 (MIB-1) in endometrial cancer 
[124, 125]. These parameters have been found to give additional information 
concerning prognosis and are widely used in decision making of treatment of these 
carcinomas. However the clinical implications of these factors are not yet clear in VC 
[115].  
 
DNA ploidy 
Two cytometric methods are generally used to determine ploidy - Flow Cytometry 
(FCM) and Image Cytometry (ICM). Both methods can be used on fresh frozen tissue 
or formalin-fixed paraffin embedded material. The most common method is FCM.  
The cell nuclei are stained with fluorochrome and quantification of the nuclear 
fluorescence is done by the flow cytometer. The amount of DNA in the cell is 
assumed to be equal with the amount of fluorescence [126]. An advantage with this 
method is the possibility of rapid analyses of large cell populations (20000 nuclei per 
specimen). A disadvantage with FCM is the inability to separate normal and tumour 
cells. 
ICM  is based on Feulgen-staining, a method first described by Feulgen and 
Rosenbeck 1924 [126]. The DNA staining is measured on microscopic slides and 
100-500 whole cells are selected for analysis. By this method it is possible to analyse 
small cell populations with large stromal components which can be difficult with 
FCM since they can be overlooked. 
DNA ploidy has been used in predicting tumour behaviour and prognosis in various 
malignancies [127-129]. Quantitative measurements of DNA content are used in 
order to detect major abnormalities in DNA content (DNA ploidy). The normal 
human somatic cell with 46 chromosomes (23 pairs) is referred to as diploid. A cell 
with fewer or more than 46 chromosomes are referred to as aneuploid. In general, 
peridiploid (near diploid) tumours, i.e. tumours with only minor deviations in DNA 
ploidy, compared with normal diploid tissue, have a good prognosis in many 
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malignancies, whereas major aneuploid tumours are associated with poor survival 
[127, 129]. 
 
S- Phase Fraction (SPF) 
Although there is no single optimal method of measuring the proliferative activity in 
tumour cells, estimation of the SPF by FCM has been of prognostic importance and 
widely used [130].  S phase is a part of the cell cycle in which DNA synthesis occurs 
before mitosis. Measuring the SPF by FCM determines the percentage of cells in this 
phase of the cell cycle [131, 132] and gives a measure of the proliferation. 
 
Ki-67 
The proliferative capacity of tumour cells is the fundamental feature of growing 
tumours, and estimates of cell proliferation provide more objective prognostic 
information. The growth of a tumour is determined by the balance between 
proliferation as the growth fraction and cell cycle time on one hand, and cell loss, 
which is the result of apoptosis and necrosis on the other. 
The Ki-67 gene encodes for the nuclear Ki-67 antigen which is present in all phases 
of the cell cycle except G0 and the early part of G1 [133, 134]. Thus the Ki-67 antigen 
is present in proliferating cells and absent in resting cells. IHC methods for detection 
of antigens associated with cell proliferation have been developed. A monoclonal 
antibody against the Ki-67 antigen (MIB1) has proven valuable by allowing direct 
monitoring of the growth fraction of normal and neoplastic cells in routinely 
formalin-fixed paraffin-embedded specimens by IHC detection [135].  
 
1.8 PROTEOMICS 
After the human genome sequence was determined, the interest moved to the analysis 
of the protein complement of the genome (proteomics) [136]. The term proteome was 
first coined  by Wilkins et al 1994 [137] and refers to all proteins in a cell, tissue or 
organism. The correlation between DNA sequence and proteins is low, reflecting 
alternative splicing as well as post-translational modifications, which explains the 
existence of a huge number of proteins.  Simplified it can be said that the genome 
describes what can happen, the transcriptome what appears to happen, the proteome 
what makes it happen and finally the metabolome what has happened and is 
happening giving the phenotype  [138].   
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As in many other cancer forms,  biomarkers for diagnostics prognostic and 
therapeutic guidance are needed in VC. During the last years, different genes have 
been traced that, in changed conditions can not only induce tumours but also affect 
their spread and growth. It is difficult and sometimes impossible to connect specific 
cell functions to specific gene alterations since each gene can produce several kinds 
of proteins.   
 
1.8.1 Two dimensional gel electrophoresis (2 DE) 
Using 2 DE,  proteins are separated in two dimensions based om the isoelectric point 
pI and size.  In the first dimension a gradient of pH is applied to a gel and an electric 
potential is applied across the gel, making one end more positive than the other. At all 
pHs other than their isoelectric point, proteins will be charged. If they are positively 
charged, they will be pulled towards the more negative end of the gel and if they are 
negatively charged they will be pulled to the more positive end of the gel. In the 
second dimension is the relative molecular mass determined using sodium sulphate-
polyacrylamide gel. The proteins are visualized in the gel by staining with e.g. 
Brilliant blue or silver. Protein spots of interest are identified using mass 
spectrometry [139, 140].  
 
1.8.2 Mass spectrometry (MS) 
Recently MS based workflow has become increasingly common and is used to study 
protein identification and quantification. 
Briefly, a mass spectrometer separates ions in the gas phase based on their mass to 
charge ratio (m/z). All mass spectrometers are essentially composed of three major 
components; an ion source, a mass analyzer and a detector (figure 4). 
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Figure 4.   Schematic overview of a mass spectrometer (reproduced  with permission 
from the thesis of Maria Pernemalm) 
 
 
 
 
 
There are two different approaches in MS based proteomics. In top-down proteomics, 
intact protein ions or large protein fragments are subjected to gas-phase fragmentation 
for MS analysis. In bottom-up approaches, purified proteins, or complex protein 
mixtures are subjected to proteolytic cleavage, and the peptide products are analyzed 
by MS. 
 
To help interpret the proteomics data, which comes out as a long list of identified and 
quantified proteins, bioinformatic tools have to be used. Example of such databases 
are Gene ontology (GO) and The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [141]. In comparative proteomic studies, the data 
mining steps are often confined to proteins measured in all samples as protein 
quantification generally is made relative to the other samples. Comparative clinical 
proteomics has to deal with large inter-individual variation. Consequently patient 
groups often need to be large in order to detect differences between groups. Although 
many proteins are detected in each sample, protein overlap is not necessarily large.  
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2 AIMS OF THE STUDY 
The general aims of this thesis were to get increased knowledge of etiologic, 
diagnostic and prognostic factors in vulvar cancer. 
 
The specific aims of the individual studies were: 
 
 
• To assess the clinical value of a preoperative lymphoscintigram during the 
SN-procedure, and to determine the detectability of SN and the false negative 
rate using radio colloid and blue dye.   
 
• To evaluate the proportion of HPV-positive and HPV-negative VSCC 
including SN, and to compare survival in the two groups. 
 
 
• To investigate the prognostic impact of ln-5 γ 2 chain expression in relation to 
clinicopathological factors and HPV status as well as DNA ploidy and 
proliferative activity (Ki-67, SPF) in primary VC. 
 
• To explore the proteome characteristics of HPV- positive versus HPV-
negative VC, protein and pathway profiling on a global and individual tumour 
level searching for markers reflecting recurrence. 
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3 MATERIAL AND METHODS 
 
3.1 STUDY SUBJECTS 
All four studies are based on a group of 85 women with invasive VC, T1-T3 without 
palpable lymph nodes who were operated at Karolinska University Hospital, Solna by 
(two surgeons) during the years 2000 to 2007 (table 3). 
Paper I and II  
The 77 women who underwent surgery with the SN procedure 
Paper III 
The group of 85 women who underwent surgery due to vulvar cancer  
Paper IV 
Fresh frozen tissue samples from a subset of 7 HPV -positive and 7 matched HPV-
negative vulvar tumours. 
 
Table 3. Characteristics of the 85 participating women with invasive VC, T1-T3 
 
Variable number % 
Age (years) Mean 71,4 range 40-92 
FIGO stage 
     I      
     II 
    III   
    IV 
 
20 
36 
23 
6 
 
23.5 % 
42.4 % 
27.1 % 
7.0 % 
Position of the tumour 
  Lateral 
  Central□ 
 
30 
55 
 
35.3% 
64.7% 
Tumour length (mm) 28.06 range 1-95 
Tumour width (mm) 22.12 range 1-70 
Operation in vulva 
Vulvectomy 
Hemivulvectomy 
Wide local  excision 
 
38 
29 
18 
 
44.7% 
34.1% 
21.2% 
Operation in groins 
Unilateral 
Bilateral 
 
25 
54 
 
30.6 % 
63.5 % 
Histopathology 
  well differentiated 
  moderately differentiated 
  poorly differentiated 
  unclassified 
 
18 
28 
37 
1 
 
21.4 % 
33.3 % 
44.7 % 
1.2 % 
Infiltration deep mean mm 9.5 range 1-45 
LVSIº 20 23.5% 
Lymph node metastasis 
   Periglandular growth 
24 
9 
28.2% 
10.6% 
Surgical margins 
   Intact  
   Invaded  
 
75 
10 
 
88.2% 
11.8% 
HPV-status 
    HPV-pos 
    HPV-neg 
    missing 
 
29 
55 
1 
 
65.5 
33.3 
1.2 
□ defined ac < 1cm from midline.   º Lymph Vascular Space Involvement. 
   19 
 
3.2 SENTINEL NODE IDENTIFICATION AND SURGICAL TREATMENT  
Patients underwent preoperative lymphoscintigraphy and injection of blue dye, 
alternatively only blue dye. Lymphoscintigraphy was performed in the morning of the 
day of surgery, 40 mBq human serum albumin colloid, labelled with 99mTc 
(NANOCOLL, Nycomed Amersham Sorin S.r.l., Saluggia (Vercelli) Italy), was 
injected intradermally at four sites around the tumour. Immediately thereafter, a 30-
min dynamic A-P acquisition was initiated with 1-min frames using one head of a 
Triad XLT gamma camera equipped with a parallel-hole collimator (Trionix Inc., 
Twinsburg, OH, USA). This was immediately followed by a static 5-min acquisition. 
The site(s) of the detected hot nodes were marked on the skin and the patients were 
operated 2-5 hours after the injection. Fifteen minutes prior to the skin incision, blue 
dye (metyltionincloride, 10mg/ml, ATL, Sweden) was injected intradermally around 
the tumour at the same four sites as used for the injection of the radioactive tracer. 
The groins were explored using a handheld γ-probe (Europrobe®, Eurorad, France) 
and dyed lymph nodes were identified macroscopically. Each lymph node containing 
radioactivity and/or blue dye was removed and considered as an SN. Thereafter, a 
complete inguinofemoral lymphadenectomy was carried out; bilateral excision was 
performed if the tumour was central (<1 cm from the midline), otherwise the excision 
was unilateral. Finally a vulvectomy or wide radical excision was performed. All 
patients with positive lymph nodes received subsequent adjuvant treatment with 
radiotherapy. 
 
3.3 HISTOPATHOLOGICAL EXAMINATION 
All SN specimens were sent separately for histopathological examination. They were 
cut in 2-3mm slices, or if larger than 4mm, divided in two along the axis, and then 
paraffin embedded. All blocks were serially step-sectioned at levels: one section per 
500 µm, 4 µm thick, three sections at each level were stained with H&E.  If no cancer 
was detected, the last one was used for IHC with cytokeratin antibodies to exclude 
metastases. We used standard sectioning and H&E staining of the primary tumours 
and the non-sentinel nodes. 
 
3.4 PCR FOR DETECTION OF HPV DNA 
DNA was extracted from 30μm pre-treatment paraffin embedded tumour slices with 
the High Pure RNA paraffin kit (Roche Diagnostics), [142]. Blank samples were 
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taken and treated in the same manner to rule out cross-contamination between 
samples. Amplifiable DNA was confirmed by PCR for the human housekeeping gene 
[142]. Presence of HPV DNA was tested by using general primer pairs, GP5+/6+ and 
CPI/IIG, as described [143, 144]. In addition, all samples were tested by HPV -6, -11, 
-16, -18 and -33 type specific primers [145] to detect false HPV-negative samples by 
general primers. Samples positive for HPV with general primers and negative for 
HPV type specific primers, were sequenced for determination of the HPV type on the 
amplicon generated from these primers, as described by Mellin et al.[146]. 
 
 
3.5 IMMUNOHISTOCHEMISTRY (IHC) 
IHC studies of Laminin-5γ2-chain and Ki-67 as well as the analyses of  STAT 1, 
PSMA 5, MX 1, and LGMN –proteins found by proteomics was performed using the 
standard peroxidase avidin-biotin-complex technique (Vector, Elite Standard Kit, 
catalog PK-6100, Vector Laboratories, Inc., Burlingame, CA) described earlier [115, 
129, 147]. 
Sections of 4 µm thick paraffin-embedded specimens of the tumours were examined. 
We used monoclonal antibody (Dako, Mo a Hu laminin- 5 γ2 chain, Clone 4G1) for   
Ln-5γ2-chain, monoclonal mouse anti-human Ki-67 antigen, clone MIB-1 for Ki-67. 
Primary antibodies against STAT1, PSMA5, MX1 and LGMN were generated by the 
Human Protein Atlas Project [148] . 
The IHC reactions was estimated and visually scored (0 to 3+) by two investigators 
from whom the histopathological data of the patients was unknown. To declare a 
lesion positive, >1% of the cells had to show distinct cytoplasmatic immunoreaction 
and be regarded as positive. 
The evaluation of ln-5γ2-chain, Ki-67 was estimated and categorized as described 
previously [115, 147] and as follows: negative ( < 1% of the tumour cells were 
positive) + (low) = (> 1% to < 25% of the tumour cells were positive); ++ (moderate) 
= (> 25, 1% to < 75% of the tumour cells were positive); +++ (high) = > 75% of the 
tumour cells were stained. The evaluation of STAT1, PSMA5, MX1 and LGMN was 
given in percentage of the stained tumour cells per total area of the tumour cells of the 
sample preparation. Staining intensity was grading using a scale from 0-3; with 0 
representing negative staining and 3+ strong staining. 
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3.6 DNA PLOIDY AND S-PHASE FRACTION BY FLOW CYTOMETRY  
A previously published improved Hedley-method [149]) for the preparation of 
paraffin-embedded tissues for flow cytometric DNA analysis has proved useful for 
the examination of various types of tumour tissues [150].  
DNA ploidy analysis and SPF was performed in paraffin-embedded formalin-fixed 
tumour specimens from 85 women with VSCC, and 67 were evaluated. 
Histopathological Sections (80 µm) were cut, and dewaxing and rehydrating were 
done by running the machine overnight. Two changes of xylene and two changes of 
ethanol in a sequence of 100, 95, 70, and 50% were made at room temperature. Each 
incubation lasted 1 hour. 
The Sections were then washed twice in distilled water for 20 min and were finally 
placed into 1 ml subtilisin Carlsberg solution for enzymatic digestion (0.1% Sigma 
protease XXIV, 0.1 M Tris, 0.07 M NaC1, pH 7.2) in a water bath at 37°C. The 
incubation time was 0.5 to 2 hours depending on the type of tissue. The yield of cell 
nuclei in the solution was checked microscopically. After incubation without shaking, 
the samples were finally shaken for 20 min.  
The samples were analyzed after a staining time of at least 1 hour and up to 8 hours at 
room temperature. Staining was carried out by adding 1 ml DAPI-phosphate solution 
(10 µM DAPI, 800 mM disodium-hydrogenphosphate) directly to the 1 ml subtilisin 
Carlsberg solution containing the sectins and the suspended nuclei (final 
concentrations in the mixture: 5µM DAPI, 0.05% subtilisin Carlsberg, 400 mM 
disodiumhydrogenphosphate, 0.05 M Tris, 0.045 M sodium chloride, pH 8.2).  
The samples were analyzed with a LSRII Flow cytometer (BD Bioscience, 
Stockholm, Sweden). The fluorochrome DAPI was excited in the ultraviolet (350-400 
nm) and the fluorescence was measured in the blue region (>435 nm). 
Usually at least 10,000 nuclei were analyzed from each sample at a measuring rate of 
about 500 nuclei/sec. If, for example, diploid nuclei are measured in channel number 
70, a broad range of higher ploidies can then be analyzed in the same histogram. The 
corresponding G1 and G2 peaks can be easily correlated to each other using the linear 
x-scale. 
A multicycle program applied for histogram analysis (Phoenix Flow Systems, San 
Diego, CA, USA) was used for calculating the percentage of nuclei after subtraction 
of sliced nuclei background. 
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3.7 PROTEOMIC ANALYSES 
3.7.1 Protein digesting and iTRAQ labelling  
Stable isotopic labels, iTRAQ (isobaric tags for relative and absolute quantification) 
were used for mass spectrometry based quantification. Each tumour sample was 
digested with trypsin and labelled with 8-plex iTRAQ. Pre-fractionation by isoelectric 
focusing to increase proteome coverage.  
To reduce sample complexity, the iTRAQ labelled peptides were separated based on 
their isoelectric point, and only peptides in the pI interval 3.7-4.9 were used for 
identification and quantification. 
 
3.7.2 Liquid chromatography – Mass Spectrometry/Mass Spectrometry 
(LC-MS/MS) analysis 
LC-MS/MS is bottom-up proteomics preceded by LC. An online HPLC-MS 
performed on a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo Fischer 
Scientific, San Jose, CA, USA). A reversed-phase separation was done. The peptides 
were then analyzed by tandem mass spectrometry MS/MS in the Orbitrap where the 
peptide sequences were determined. The peptides were separated according to mass 
partially fragmented into amino acids and the fragment spectra together with the 
precursor mass is then used to determine the amino acid sequence of each peptide. 
 
3.7.3 Protein identification and quantification 
All MS/MS spectra with the identified peptides were searched against protein 
sequence databases to match the peptide sequences with known protein sequences, 
Mascot 2.2  [151]  (Matrix Science Limited, London, UK) under the software 
platform Proteome Discoverer 1.1 (Thermo) against the NCBInr human target decoy 
(20090118). As decoy the reversed sequences were used. Searches were also done 
against a merged human and virus target decoy database. There were however no 
virus hits, so subsequent searches were done against a database composed of only 
human sequences. 
Quantification of iTRAQ-8plex reporter ions was done by Proteome Discoverer 
(version 1.2) on the tandem mass spectra. 
The scores and the original peptide lists were then further curated using the in-house 
developed software PQPQ . The program uses the quantitative pattern of samples to 
match peptides to proteins, based on the assumption that peptides originating from the 
same protein show a similar pattern. This makes it possible to use also low-scoring 
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peptides and low- intensity peptides without compromising in confidence. All protein 
quantified by PQPQ had an identification based on at least two peptides, and at least 
one of the peptides being above the score limit. 
 
3.8 STATISTICAL AND DATA ANALYSIS 
Paper I and II 
Statistical analyses were performed using SPSS 17.0 for Windows (Chicago, Ill.USA 
2008). 
Means between groups were compared using Student’s independent t-test and 
distribution between groups using the chi-square exact test. Survival was evaluated 
using the life table method taking censored observations into account. 
Univariate comparisons were made using the Gehan-Wilcoxon method.  
Multivariate survival analyses were performed using Cox regression. 
Weighted kappa was calculated to give a measure of agreement between SNs found at 
scintigraphy and those found at surgery [152].  
Paper III 
Statistical analyses were performed using SPSS 18.0 for Windows (Chicago, Ill. USA 
2008).  
Disease-specific survival was evaluated with Cox regression model.  
Relations between considered factors were analysed with Spearman`s correlation. 
Survival graph was constructed using the Kaplan-Meier method and tested with 
Gehan-Wilcoxon exact test.  
Paper IV 
Students t-test was performed using SAM (Significance Analysis of Microarrays) for 
Excel version 3.09 [153].  
Multivariate statistics and modelling [154] was performed with SIMCA (SIMCA-P+ 
12.0, Umetrics, Sweden).  
The unsupervised principal component analysis (PCA) [155, 156] was done to obtain 
an overview of the data, detect clustering of the data and to pick up outliers if any.  
The supervised analysis (orthogonal partial least square analysis, O-PLS) [157] of the 
dataset was used for classification and identification of proteins separating HPV- 
positive from HPV-negative or relapse from relapse-free tumours/patients.  
Hierarchal clustering 2-ways; protein ID and sample was performed using the  
freeware Genesis version 1.7.6 [158].  This is a statistical method that is based on 
measured variables capable of identifying relatively similar groups of samples.  
 24 
Gene Ontology (GO) annotation was performed using ProteinCenter™ (Proxeon 
Biosystems, Odense, Denmark) and The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [141] . 
Pathway analysis to further examine protein quantity alterations, network building as 
well as matching to canonical pathways was performed using the web based software 
from Ingenuity Systems; Mountain View, CA, USA (Ingenuity Pathway Analysis, 
IPA, www.ingenuity.com). In brief, matching of proteins from the data set was done 
against the Ingenuity pathway database of known (canonical) pathways. The degree 
of matching was ranked by p-values. The analysis was performed both on a data 
subset consisting of only proteins shared between all samples, as well as on protein 
profiles from individual tumours (figure 6).  
 
 
 
 
  
 
 
 
 
 
 
Figure 6. An overview of the data analysis workflow in the proteomic analyses 
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4 RESULTS AND DISCUSSION 
4.1 PREOPERATIVE LYMPHOSCINTIGRAPHY AND SENTINEL NODE  
A total number of 130 groins in 77 patients were operated. Our study is one of the 
largest performed at one single centre (n=77) [68-70, 75, 159]. All patients were 
operated by one or both of two surgeons. With the intention of obtaining experience 
and since a complete lymph node dissection was always performed, we allowed wide 
inclusion criteria. Today, we have learnt from our own experience as well as from 
others’ that some patients are not suitable for the SN technique [76]. 
 
4.1.1 Preoperative lymphoscintigraphy 
In two cases SNs were not visualized by lymphoscintigraphy presurgery, however, in 
one of these, SNs were identified with blue dye during surgery. In one of the 17 cases 
where blue dye alone was used, no dyed node was found. Thus the detection rate for 
the combined method with both radioisotope and blue dye was in our material 98% 
compared to 94% with blue dye alone that is similar to other reports [69, 160, 161].  
The relation between the number of SNs shown on the scintigram and the number of 
SNs identified at surgery showed good agreement using weighted kappa [152]. 
Preoperative scintigraphy is in our experience helpful to identify the location and 
numbers of the lymph nodes especially when several SNs are visualized.  The 
preoperative scintigram gives the best estimate available for detection of the accurate 
number of SNs.  In some cases, however, we were not able to detect all the nodes that 
were shown on the scintigram and in some cases we found a larger number of SNs 
during operation than had been shown on the scintigram. One possible explanation 
could be that the nodes are located at different depths and thus hiding each other on 
the scintigram. In the ALMANAC trial (breast cancer) they found that SN biopsy-
success decreases when there is non-visualisation of hot nodes on the pre-operative 
lymphoscintigram. [162, 163] 
 
4.1.2 Identification of SN 
During surgery at least one SN was identified in 94 of 126 groins in (in 75 patients 
excluding two patients with unsuccessful detection). Twenty-three patients (31%) had 
metastases in the groins and out of them 7 were bilateral, giving 30 affected groins. 
The SNs contained metastases in 20 groins. Two of these were micro metastases 
found by IHC. In 13 groins the SNs were the only positive node(s). 
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4.1.3 False negative SN 
Out of 74 groins with a negative SN, two contained positive non sentinel nodes. This 
is in agreement of other results, thus false negative rate was 2.7% [62, 68-70, 75, 80]. 
In breast cancer surgery the rate of false negative SN decreases from 10% to 3% if the 
first 30 operations of each surgeon are excluded [79]. Our two false negative SNs 
appeared in 2002 and 2005, respectively. A possible explanation for false negative 
SNs is that the SNs are full of cancer and the nanocolloid pass through the SN to 
other lymph nodes [76].  The two false negative cases both had large midline tumours 
and one of them was multifocal. Both patients had 3 and 5 metastases respectively in 
the groin with negative SNs a phenomenon  reported earlier [164].  Furthermore 
multifocal lesions have shown to be less suitable for the SN method [76] 
 
4.1.4 Direction of lymphatic drainage 
Lymphatic drainage was unilateral in 40 out of 58 patients (69 %) who had a 
successful lymphoscintigraphy, including all 16 patients with lateral lesions. Out of 
42 patients with midline tumours, only 18 (43%) had bilateral lymphatic drainage at 
scintigram. This is in agreement with other studies [68, 75, 165, 166]. We did not 
differ between tumours close to midline and tumours abutting the midline as they did 
in a study by Haupsy [75]. In clinical practice (before sentinel node) the general rule 
has been to perform bilateral ingunofemoral lymphadenectomy in women with 
tumours <1cm from midline. The results of van der Zee et al and  Haupsy et al 
indicate that only tumours abutting the midline have bilateral lymph flow, and it is 
safe to refrain groin dissection in the contra lateral groin without detectable SN in 
cases with tumours close to midline (<1cm) but not engaging midline [75, 76].  
 
 
4.1.5 Size of tumours 
Large tumours are more likely to have metastases which can change the lymphatic 
drainage [164, 167]. The only patient with a small (15mm) primary tumour on the left 
area of clitoris had previously undergone a local excision and the remaining tumour 
was 6mm. It has been reported that  a scar after a previously removed lesion can 
hamper the SN identification in the groins [69] while this is not the experience of 
others [75]. 
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In a European multi centre observational study by van der Zee et al, 259 patients with 
unifocal vulvar tumour ≤4cm and negative SN were followed up for 2 to 87 months 
with respect to groin recurrence. Only six recurrences (2.3%) were diagnosed [76].  If 
we have used same selection criteria as in this study only one of our patients with 
false negative or unidentifiable SN would have been included. 
 
4.2 DISTRIBUTION OF HPV 
HPV DNA was detected in 23 (31%) of the primary tumours. Patients with HPV-
positive tumours were significantly younger (mean age 64 years) than those with 
HPV-negative tumours (mean age 75 years) and they also had smaller lesions. Single 
infections with HPV 16, 18, 33 and 52 were detected in 16, 2, 2, and 1 of the tumours 
respectively. In addition, there were two double infections, one with HPV 16+33 and 
the other with HPV 18+33. Ten (43%) of the 23 patients with HPV-positive tumours 
also had HPV in their SN.  
Seven out of ten HPV-positive SN from HPV-positive tumours contained HPV 16, 
and one typed HPV 18, in concordance with the types in the tumours. In the two 
remaining cases it was impossible to classify the HPV type by sequencing. In 
addition, one patient with an HPV-negative tumour had an HPV-positive SN of type 
16.  
 
To our knowledge, this is the first report on HPV prevalence in VSCC in Sweden. 
Data from other Nordic countries shows similar results. In a report from Finland a 
prevalence of 36% of HPV in VSCC was found [18], while a report from Norway 
[21], showed 22% HPV prevalence. Furthermore, a report from Denmark 
demonstrated a prevalence of 52% in a subset of 60 patients diagnosed  1993-1998 
[22]. This previously published data is fairly similar to ours but there may be some 
sources of error when comparing HPV prevalence data, such as the selection of 
VSCC patients according to age or survival. In the Danish study there may have been 
considerable selection since only surviving patients were included, which is reflected 
in the low mean age (63 years) of the patients. This may also explain the high 
prevalence of HPV. Another confounder may be the fact that the materials compared 
were collected during different decades. A recent report on tonsillar cancer in 
Stockholm, Sweden, showed that there has been a significant increase in HPV 
prevalence during the last decades, and even between 2000 and 2007 [102, 103]. It 
may be possible that the same trend is also true for VSCC. This may explain the 
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slight discrepancy between our data and the Norwegian data collected between 1977 
and 1991 [18, 22]. An additional confounder may be different detection methods and 
patient numbers. DNA in formalin-fixed, paraffin embedded tissue specimens is often 
degraded to fragments smaller than 250 base pairs because of fixative-induced cross-
links. Only PCR assays generating relatively short PCR products can be reliably 
applied to this material. 
Various PCR and read-out assay combinations display variable analytical properties, 
particularly in terms of sensitivity for the detection of the HPV types. The method we 
used works with 188 base pair. Our material is relatively fresh and collected during 
less than a decade. In concordance with previous studies, HPV 16 was the dominant 
type in the tumours and SN, and no tumours were positive for low-risk HPV types 
[23, 105] . 
 
 
4.3 SIGNIFICANCE OF HPV FOR SURVIVAL AND METASTASIS 
We found that patients with HPV-positive primary tumours had significantly better 
survival than those with HPV-negative tumours (p=0.001). Even when adjusted for 
age and tumour size the p-value was 0.030.  Disease-specific survival was 
significantly different with respect to HPV status (p=0.004, exact test) (Figure 7). In 
fact none of the patients with an HPV-positive primary tumour died of disease, while 
18/52 patients with HPV-negative tumours died during the follow up period, in spite 
of the lack of difference between the proportions of lymph node metastases between 
the two groups (35% and 26% respectively). A better prognosis for patients with 
HPV-positive tumours has been indicated in some studies [21, 102, 103], while other 
investigators found that HPV status had no prognostic significance [20, 68, 105]. 
Recurrence-free survival in relation to HPV did not reach significance when age and 
tumour size was included in the statistic analysis. 
In patients with HPV-positive tumours, metastatic SNs were significantly more often 
HPV-positive (5/5) as compared to those without metastases (5/18) (p=0.007) (Figure 
7). No prognostic significance of HPV presence in SNs was detected; however the 
size of the material is too small to draw any conclusions. 
 
Notably, we also observed that HPV was present in one case in an SN, but not in the 
corresponding primary tumour. This was confirmed for both the SN and the primary 
tumour by Multiplex Luminex [168]. The HPV-positive SN in the patient with an 
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HPV-negative tumour might be explained by an HPV infection not correlated with 
the malignancy.  
To our knowledge, the presence of HPV in SN has never before been investigated in 
VSCC, although previous studies have investigated the presence of HPV DNA in 
lymph nodes in general [20, 23]. Pinto and co-workers assessed HPV status 
retrospectively in lymph nodes in a subset of 30 cases of HPV-positive and 13 cases 
of HPV-negative VSCC, and found HPV in lymph nodes from 10 patients with HPV-
positive tumours. In all 10 cases, lymph node metastases were also found [20]. Sutton 
et al. tested metastatic nodes from 11 cases of HPV-positive tumours and detected 
HPV in 9 of them [23]. This is in accordance with our results that 5/5 metastatic SNs 
contained HPV (figure 8). 
In cervical cancer, HPV status in SNs has been examined by Coutant and co-workers 
in 59 patients [81]. They found that HPV DNA was more frequently found in 
metastatic SNs compared to non-metastatic SNs. Lee and co-workers [82] examined 
57 patients and found that absence of HPV in SN had negative predictive value for 
lymph node metastasis and recurrence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Disease specific survival by HPV-status of the primary tumour (p=0.04, 
exact test)  
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Thus, data from HPV testing of lymph nodes in general in vulvar cancer as well as 
the testing of SNs in cervical cancer are in agreement with our results. HPV positivity 
in lymph nodes in vulvar and cervical cancer is associated with metastatic 
involvement. The prognostic significance HPV DNA in pathologically negative 
lymph nodes (LN) is uncertain. It can be speculated that they represent a clinically 
significant group of micro metastases that have not been detected or caused by 
migrating disintegrating tumour cells that contain viral DNA.  In cervical cancer a 
large prospective study has confirmed a direct correlation between the presence of 
HPV in LN and worse prognosis [169], whereas other small retrospective studies did 
not [170]. Maybe HPV typing of SN could play a supportive role to reduce the false 
negative rate in patients with HPV-positive tumours.  Larger studies with longer 
follow up and standardization of testing native and formalin embedded material are 
needed to evaluate the prognostic significance of HPV DNA in SN.  
 
 
 
 
 
 
 
 
 
 
  
.   
 
Figure 8. HPV-positivity (%) in SN of 69 VSCC 
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4.4 SIGNIFICANCE OF MOLECULAR MARKERS AND PLOIDY 
4.4.1 Laminin-5 γ2-chain 
The staining was observed in cytoplasm of the cancer cells along the invasive front 
and to isolated cancer cell clusters invading the stroma. Ln-5γ2-chain expression was 
not found in the stromal cells or in the basement membrane.  
Out of 76 tumours evaluated for ln-5y2-chain, seven (9.2%) tumours showed no 
expression, while 30 (39.5%) tumours showed low, 20 (26.3%) moderate and 19 
(25.%) high expression respectively. In the statistical analyses in survival tumours 
with ln-5y2-chain no, low or moderate expression were grouped together and 
compared to tumours with high ln-5y2-chain expression. 
Ln-5y 2 chain showed positively significant correlation with stage (p=0.044), tumour-
size (p=0.012), differentiation grade (p=0.003), metastases (p=0.016) and was 
negatively associated with HPV status (p=0.034).  High expression of ln-5y 2 chain 
was more often seen in HPV-negative tumours than in HPV-positive tumours.  
In the univariate analyses regarding the different factors, ln-5y2 chain and HPV-status 
had significant impact on survival. Analysing these two factors together in a Cox 
regression model, both of them showed independent impact on survival.  
When considering other clinical and histopathological factors showing impact on 
survival and including them in a stepwise logistic Cox regression analysis only HPV 
status and tumour stage were significant factors for survival. Competing non 
significant factors were age, tumour-size, metastases, and ln-5γ2 chain.  
Various polyclonal and monoclonal antibodies against the ln5 γ2 chain have been 
used as markers of invasive cancer in e.g. colorectal carcinomas [116, 120] and SCC 
[113]. Ln-5 γ2 chain expression has also been demonstrated as an indicator of 
microinvasiveness in cervical carcinoma [114], and pancreatic carcinoma [171]. In 
our study we used a monoclonal antibody against y2-chain of ln-5.  
Ln5 γ2 chain expression was reported to indicate the invasive potential of 
precancerous lesions of the anogenital tract [115]. Similar results have been reported 
in cancer in situ lesions of the larynx [172]. Thus, ln-5γ 2 chain expression seems to 
be up-regulated in most invasive tumours especially squamous malignancies but 
down-regulation has been reported in prostate [173] and breast carcinomas [174, 
175]. 
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It is known that there is a correlation between ln-5y2 chain expression and the 
survival in various malignancies such as vagina tongue, lung and anal cancer [119, 
176-178]. HPV negativity and high expression of ln-5y2 chain were associated with 
poor outcome. In a study of  89 cervical cancer including both squamous and 
adenocarcinoma no correlation of ln-5y2 chain and survival was found, and no 
difference concerning ln-5y2-chain expression between HPV- positive and HPV- 
negative tumours [175]. Furthermore, 98% and 69% of the tumours respectively were 
HPV-positive in contrast to our 34%. 
 
4.4.2 Ki 67 (MIB 1) 
Ki-67 expression was evaluated in 70 tumours and all were positively stained. The 
expression was low, moderate and high in 40 (57.1%), 24 (34.3%) and 6 (8.6%) 
respectively. Ki-67(MIB1) was significantly correlated to HPV (p<0.001), which 
means that Ki-67 was over expressed in HPV-positive tumours.  
This is in agreement with Hoevenaar’s et al study on usual and differentiated VIN-
lesions; all 38 cases of HPV-positive usual VIN lesions showed high expression of 
MIB-1 in contrast to 3 of 75 HPV-negative differentiated VIN [179]. 
In paper II we proposed a better prognosis for HPV-positive tumours compared with 
HPV- negative tumours [101]. This is consistent with this study where HPV status 
showed significant impact on survival in a univariate analysis as well as in a stepwise 
Cox regression analysis. 
 
4.4.3 DNA ploidy and SPF 
DNA ploidy and SPF were analyzed in 67 patients. The majority, 50 (74.6%) of the 
tumours were diploid and 17 (25.4%) tumours were aneuploid. SPF, was low (<10%) 
in 56 (83.6%) and only 11(16.4%) tumours had a high (>10%) SPF. 
The majority of the tumours had a low (<10%) SPF.  No correlation was found 
between ploidy and survival, which is in accordance with previous investigations [19, 
180] except for one study there a significant correlation was found in stage I and II 
but not in stage III and IV [181]. 
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4.5 PROTEOMIC ANALYSIS 
 
We describe a workflow in which tumour protein levels determined by mass 
spectrometry based proteomics was analysed by two data mining approaches:  
• Group wise comparison of altered protein between HPV infected and negative 
tumours and relapse versus relapse-free tumours and  
• Pathway profiling for each individual tumour based on altered protein levels 
on the hypothesis that individual molecular networks drive tumour growth in 
each tumour. Comparison of pathways between samples was possible by 
analysing the ranking for each pathway-match by a supervised multivariate 
analysis. The aim was to identify key pathways involved in VSCC without 
losing information as may be the case in a group analysis limited to 
overlapping proteins.  
 
By using MAYU with a FDR of 5%, 4065 protein entries were considered accurate in 
terms of identification. Out of these, 1579 were accurately quantified according to 
PQPQ [182], 449 proteins were present in all 14 samples.  They were compared to the 
mean of the internal standard and were used for the multivariate discriminant analysis 
and the group wise pathway analysis. A total of 1566 protein entries were included. 
 
4.5.1 Classification based on HPV and relapse status 
Student´s t-test identified 4 differently expressed proteins: Collagen type I alpha 2 
and alpha 1; periostin osteoblast specific factor and fibrillin 1 as significantly up-
regulated in HPV- positive tumours at an FDR of 22%.  
We also sought the protein pattern that could discriminate between relapse and non-
relapse cancer groups, irrespective of HPV status. Four proteins were significantly 
up-regulated in relapse (n=5) compared to the non-relapse patient group (n=7) by 
student´s t-test at an FDR of 27%. These proteins were: tryptophanyl-tRNA 
synthetase (WARS), signal transducer and activator of transcription 1 91kDa 
(STAT1), 2´-5´-oligoadenylatcyclase (2´-5´-OAS) and myxovirus (influenza virus) 
resistance 1 interferon-inducible protein p78 (MX1). The OPLS-model based on 16 
proteins (p-value <0.007), confirmed WARS, STAT1, 2´-5´-OAS and MX1 as 
important classifiers of relapse and non-relapse tumours. There were no overlapping 
proteins between the two OPLS models based on HPV status and relapse status. 
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4.5.2 Biological interpretation of discriminating proteins 
The proteins supposed to discriminating HPV-status and relapse/nonrelapse were 
analysed using Ingenuity Pathway analysis. They were matched against a database 
consisting of known protein signalling pathways. HPV-status gave 28 significant 
pathways (p<0.05); of which 10 had a p-value <0.01. The top four were α-adrenergic 
signalling (p=0.00007), Protein Kinase A signalling (p=0.0001), caveolar mediated 
endocytosis signalling (p=0.0009) and breast cancer regulation by stathmin 
(p=0.001). 
 
The analysis of “relapse/non-relapse” revealed 11 significantly altered pathways 
(p<0.05). The most significant was the IFN signalling pathway (p=0.0005), followed 
by ERK/MAPK signalling, IL-22 signalling and the protein ubiquitination pathway 
(all with p=0.03).  
 
 
 
4.5.3 Analysis on individual tumour level  
Tumour growth driving pathways are likely to form unique combinations in 
individual tumours. Pathway analysis was performed for each of the 14 tumour 
samples individually to obtain altered pathway fingerprints of each patient based on 
proteomics data. All proteins found to be up- or down regulated were included in the 
individual tumour analysis; in total 1566 protein entries. The protein profile from 
each tumour was mapped to the canonical pathways in the Ingenuity database. 
The canonical pathway analysis identified the pathways from the IPA library that 
were most significant for each of the 14 data sets. Individual pathway analysis and 
following multivariate analysis were done with HPV and relapse as class-identifiers. 
The protein level alterations in pathway “RIG-1 like receptors in antiviral innate 
immunity” was top ranked. 
 
The investigation of relapse versus non-relapse on individual tumours (pathway 
analysis combined with multivariate analysis) identified “Rac signaling” as a top 
affected pathway in non-relapse tumours, and “RIG-1 like receptors in antiviral 
innate immunity” as top affected pathway in relapse cases. Rac is member of the Rho 
family of small GTP-binding proteins that mediate ErbB responses. Rac is 
overexpressed in oral SCC [193] and overexpression correlates with progression of 
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breast [194] and gastric cancer [195]. RAC1 is activated in breast cancer cell lines in 
response to the ERBB ligands epidermal growth factor (EGF) and heregulin [196]. 
The latter study and another [197] indicates that via a protein Rex1, signals are 
integrated from both tyrosine kinase receptors and GPCRs to activate RAC activity, 
resulting in the proliferation and migration of breast cancer cells. Rac inhibition 
impairs breast cancer cell motility and proliferation in response to EGFR and ErbB3 
ligands [198, 199]. The activity of Rac is mainly regulated by guanine nucleotide 
inhibitors and exchange factors.   
The RIG1-related pathway is shown to be deregulated in relapse cases. The proteins 
FADD (Fas-associated death domain) and NF-κB that were mapped to the pathway 
are linked to poor outcome in lung adenocarcinoma. Increased levels of 
phosphorylated FADD leads to an increase of NF-κB activity, which in turn affects 
cell cycle progression [200].  
 
Significant pathways differing between HPV-positive and HPV-negative cases were 
“purine metabolism” and “glucocorticoid receptor signalling” (active in HPV) and 
“integrin-linked kinase” (ILK) (active in HPV-negative). Note that the glucocorticoid 
signalling pathway overlaps both with EGF and with STAT signalling which is part 
of the interferon pathway connected to viral infections.  
 
 
 
4.5.4 IHC staining of selected proteins 
We selected 4 proteins that were found to be deregulated in relapse VSCC (both 
HPV-positive and negative cases) for additional analysis by IHC. These were 
PSMA5, STAT1, MX1 and LGMN. Staining of HPV-negative tumours was 
significantly stronger for all proteins (p<0.05) in comparison to HPV-positive 
tumours. In contrast to what was assumed based on the mass spectrometry results 
there were no statistically significant differences observed in the IHC data between 
relapse and non-relapse. 
 
4.5.5 Group wise analysis 
The protein PSMA5 (identified in the individual tumour analysis as well as a 
discriminator of relapse versus non-relapse) is a part of the proteasomal unit which 
belongs to the protein ubiquitination pathway which was one of the top 
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discriminating pathways in the individual tumour analysis for both relapse and HPV 
status. The proteasomal unit is reported as up-regulated in many cancer cells, most 
likely because cancer cells have a need to get rid of immature and irregular proteins 
which would otherwise harm the cell. Proteasome inhibitors are approved for clinical 
use in certain cancer types (e.g multiple myeloma), but not in VSCC [183]. The IHC 
results showed no significance between relapse/nonrelapse patient groups, but in the 
comparison of HPV-positive tumours with negative, there was significantly (p<0.04) 
lower levels of PSMA5. It is possible that HPV-infected tumours have down- 
regulation of the proteasomal pathway responsible for viral antigen peptide 
presentation on MHC1 complex via PSMA5, hence highlighted as difference between 
these two tumour groups.  
This result can then justify further studies on possible therapeutic use of proteosomal 
inhibitors in HPV-negative VSCC.   
 
One major pathway identified was the interferon (IFN) signalling pathway.  
Interferons are activated in response to viral infection, and it has been shown that 
HPV infection represses the transcription of proteins downstream IFN-signalling 
[26]. In line with this, we observed lower levels of STAT 1, a key transcription factor 
in the IFN response, in the HPV-positive tumours in our IHC assay (p<0.05), figure 
6. This finding was supported in the individual-tumour analysis which identified the 
IFN pathway as one of the top-deregulated pathways among HPV-positive cases 
(figure 4). Our findings now confirm the role of IFN pathway in HPV on a protein 
level. Interestingly, three proteins of the IFN pathway were also identified as most 
important discriminators of relapse in the group-wise analysis on overlapping 
proteins; MX 1, STAT 1 and 2´5´OAS. These proteins are all IFN-inducible genes 
identical to those previously identified by microarray studied to be transcriptionally 
repressed by high-risk HPV proteins [26].  
 
There are also overlaps between several of the pathways identified in this study. 
STAT signalling is also part of the glucocorticoid pathway as well as the EGFR 
signalling pathway, which is believed to be altered in some subsets of vulvar 
carcinoma. Increased expression of HER-2 and EGFR has been found in 47% and 
67% of vulvar carcinomas [184-186]. Oonk et al have found that EGFR expression is 
related to lymph node metastasis in patients with vulvar carcinoma [187]. 
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The role of legumain (LGMN) in VSCC is unclear. It is a lysosomal protease 
(asparaginyl endopeptidase)  involved in class II MHC antigen processing [188]. The 
pathway-belonging is unknown, but has been suggested as a prognostic factor in 
breast cancer [189], where positive vesicular staining in IHC was correlated with an 
adverse outcome.  It has also been correlated to invasion and metastasis in solid 
tumours, and has been suggested as a pro-drug activator [190].  In our study, it was 
identified as a discriminator of relapse/non relapse (up-regulated in relapse) in the 
analysis based on overlapping proteins; but as an HPV/non-HPV discriminator in the 
IHC analysis, showing significantly lower (p<0.01) levels in HPV+ compared to 
HPV- tumours. A link to HPV status is the viral protein E5 which targets and 
acidifies endosomes, affecting antigen processing [191]. E5 has also been shown to 
reduce levels of MHC I at the surface possibly by interacting with BAP31 [26, 192], 
contributing to HPV-mediated immune evasion.  
Peptides are however processed differently in the MHC I and MHC II pathways. 
 
 
In our study, we could see an overlap between pathways discriminating HPV/non 
relapse and non-HPV/relapse. Several studies have indicated that patients with HPV-
positive tumours have a better prognosis (paper II). As the HPV status of a tumour is 
readily determined by PCR, the extra value of a protein marker for HPV-like 
phenotype would be showing, not the presence of HPV but more importantly where 
the HPV infection or residual E5 or E7 protein expression is plays a role in 
carcinogenesis leading to distinct tumour phenotype. In a study on Head and Neck 
Squamous Cell carcinoma (HNSCC), Weinberger et al [201] could see no predictive 
indication from HPV status alone; but when adding information of p16 levels protein 
downstream E2F, strongly correlated with HPV infection. In a retrospective study 
from Norway they found that low levels of p16/INK4A protein and high levels of p21 
protein were associated with a shorter disease-related survival [202]. HPV-status is 
unknown, but they found that the patients with high expression of p16/INK4A were 
younger, indicating the possibility of being HPV-positive. Moreover, a Danish study 
on HNSCC showed that expression of p16/INK4A, was a prognostic factor of 
treatment (radiotherapy) response and survival [203].  
 
 
 38 
5 GENERAL CONCLUSIONS 
The lymphoscintigram helps to identify and localize the SNs, but cannot determine if 
unilateral or bilateral groins should be explored. In case of a midline tumour with 
unilateral radioactive uptake a complete inguinofemoral lymphadenectomy in the side 
without SN identification should be performed. To optimize detection of SN and 
minimize the false negative detection rate the method is not recommended for 
tumours larger than 40mm.  
 
VSCC develops through two different pathways. The differences in tumour size, age 
and survival between patients with HPV-positive and negative tumours, as well as the 
presence of HPV DNA in the SN of HPV-positive primary tumours, supports this. In 
agreement with other studies, HPV types 16 and 18 were dominant in VSCC in our 
study. The newly introduced HPV vaccines may, in the future, reduce the numbers of 
VSCC associated with HPV. 
 
Ln-5 y2 chain and HPV status had significant impact on survival in vulvar carcinoma 
in a univariate analyse. HPV negativity and high expression of ln-5 y2 chain were 
associated with poor outcome. When considering other clinical and histopathological 
factors showing impact on survival and including them in a stepwise logistic Cox 
regression analysis, only HPV status and tumour stage were significant factors for 
survival.  
 
Alterations of the “RIG-1 like receptors in antiviral innate immunity” pathway may 
be linked to an unfavourable prognosis while alterations of the 
IFN/EGFR/Glucocorticoid signalling pathway is associated with HPV-positive 
tumours and thus of favourable prognosis. Validation with Tissue Micro Array 
(TMA) on a larger patient cohort is of course needed.  
This approach of analysing proteomics data the context of altered pathways may 
hence help to relate proteome data to upcoming targeted cancer therapies by revealing 
combinations of tumour growth driving pathways and molecular networks. 
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6 FUTURE PERSPECTIVES 
 
• Investigating the prevalence of HPV in VSCC over time in Stockholm 1970- 
2010 .  There are reports of increasing numbers of HPV associated VSCC in 
other countries 
• Validation with TMA on a larger patient cohort, the findings of altered 
pathways and protein expression from paper IV. 
• Studies of proteins of importance for malignant transformation, and tumour 
growth in VIN in relation to normal vulva and invasive cancer. Possibility of 
identifying patients with VIN III lesions without invasive potential can 
prevent over-treatment and save many women from mutilating surgery. 
• Examine if the de regulated proteins in the tumours can be found in serum or 
plasma preoperatively and during follow-up. This could help finding early 
recurrences. 
• Investigating the possible effect of proteosomal inhibitors as adjuvant 
treatment in HPV-negative VSCC.  
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